



US007732130B2

(12) **United States Patent**
Neiryneck et al.

(10) **Patent No.:** **US 7,732,130 B2**
(45) **Date of Patent:** **Jun. 8, 2010**

(54) **IMMUNOPROTECTIVE INFLUENZA ANTIGEN AND ITS USE IN VACCINATION**

(75) Inventors: **Sabine Neiryneck**, Lokeren (BE); **Willy Min Jou**, Destelbergen (BE); **Walter Fiers**, Destelbergen (BE)

(73) Assignee: **Vlaams Interuniversitair Instituut Voor Biotechnologie**, Zwijnaarde (BE)

(*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 132 days.

(21) Appl. No.: **11/374,922**

(22) Filed: **Mar. 14, 2006**

(65) **Prior Publication Data**
US 2006/0246092 A1 Nov. 2, 2006

(51) **Int. Cl.**
C12Q 1/70 (2006.01)
A61K 39/00 (2006.01)
A61K 39/145 (2006.01)

(52) **U.S. Cl.** **435/5**; 424/192.1; 424/204.1; 424/209.1

(58) **Field of Classification Search** None
See application file for complete search history.

(56) **References Cited**

U.S. PATENT DOCUMENTS

3,919,044 A	11/1975	Melnick et al.	
5,691,189 A *	11/1997	Kurtz et al.	435/254.21
5,843,446 A	12/1998	Ladd et al.	
5,871,747 A	2/1999	Gengoux-Sedlik et al.	
6,169,175 B1	1/2001	Frace et al.	

FOREIGN PATENT DOCUMENTS

AU	49273 90	8/1990
AU	A-49273/90	8/1990
WO	WO 92/22575	12/1992
WO	WO 94/06472	3/1994
WO	WO 98/23735	6/1998
WO	WO 99/07839	2/1999
WO	WO 01/49886	7/2001
WO	WO 01/49886 A2	7/2001
WO	WO 01/59886 A3	7/2001

OTHER PUBLICATIONS

Gerhard et al. *Emerging Infectious Diseases*, Apr. 2006, 12(4):569-574.*
 Neiryneck et al. *Nature Medicine*, Oct. 1999, 5(10):1157-1163.*
 Armerding, et al., "Evaluation of live and inactivated influenza A virus vaccines in a mouse model" *J Infect Dis* 145(3):320-30 (1982).
 Arnon, et al., "Synthetic recombinant vaccines against viral agents" *Int Arch Allergy Immunol* 108(4):321-6 (1995).
 Asanuma, et al., "Cross-protection against influenza virus infection in mice vaccinated by combined nasal/subcutaneous administration" *Vaccine* 13(1):3-5 (1995).
 Bachmayer, et al., "Potency of influenza vaccines: mouse protection experiments in correlation to field studies in man" *Dev. Biol Stand* 28:336-9 (1975).
 Baez, et al., "Gene composition of high-yielding influenza vaccine strains obtained by recombination" *J Infect Dis* 141:362-365 (1980).

Bastin, et al., "Use of synthetic peptides of influenza nucleoprotein to define epitopes recognized by class I-restricted cytotoxic T lymphocytes" *J Exp. Med.* 165:1508-1523 (1987).
 Bednarek, et al., "The minimum peptide epitope from the influenza-virus matrix protein. Extra and intracellular loading of HLA-A2" *J Immunol* 147:4047-4053 (1991).
 Ben-Ahmeida, et al., "IgG subclass response and protection against challenge following immunisation of mice with various influenza A vaccines" *J Med Microbiol* 40(4):261-9 (1994).
 Berendt, et al., "Evaluation of commercially prepared vaccines for experimentally induced type A/New Jersey/8/76 influenza virus infections in mice and squirrel monkeys" *J. Infect Dis* 136 Suppl:S712-7 (1977).
 Betakova, et al., "The NB protein is an integral component of the membrane of influenza B virus" *J Gen Virol* 77(Pt 11):2689-94 (1996).
 Bodmer, et al., "Enhanced Recognition of a Modified Peptide Antigen by Cytotoxic T Cells Specific for Influenza Nucleoprotein" *Cell* 52:253-258 (1988).
 Bottex, et al., "Comparative immunogenicity of live influenza viruses and their solubilized neuraminidases: results of mouse protection experiments" *Arch Virol* 70(2):83-9 (1981).
 Brassard, et al., "Influenza B virus NB glycoprotein is a component of the virion" *Virology* 220(2):350-60 (1996).
 Brett, et al., "Human T Cell Recognition of Influenza A Nucleoprotein. Specificity and Genetic Restriction of Immunodominant T Helper Cell Epitopes" *J Immunol* 147:984-991 (1991).
 Ceppellini, et al., "Binding of labelled influenza matrix peptide to HLA DR in living B lymphoid cells" *Nature* 339, 392-394 (1989).
 Cerundolo, et al., CD8 independence and specificity of cytotoxic T-lymphocytes restricted by HLA Aw68.1. *Proc Roy Soc Lond Series B boil Sci* 244:169-177 (1991).
 Chen, et al., "Protection against influenza B virus infection by immunization with DNA vaccines" *Vaccine* 19:1446-1455 (2001).
 Cruse, et al., *Illustrated Dictionary of Immunology*, pp. 46 and 229 (1995).
 Deck, et al., "Characterization of humoral immune responses induced by an influenza hemagglutinin DNA vaccine" *Vaccine* 15(1):71-8 (1997).
 de Haan, et al., "Mucosal immunoadjuvant activity of liposomes: induction of systemic IgG and secretory IgA responses in mice by intranasal immunization with an influenza subunit vaccine and coadministered liposomes" *Vaccine* 13(2):155-62 (1995).
 Deroo, et al., "Recombinant neuraminidase vaccine protects against lethal influenza" *Vaccine* 14(6):561-9 (1996).

(Continued)

Primary Examiner—Stacy B Chen
(74) *Attorney, Agent, or Firm*—Husch Blackwell Sanders Welsh & Katz

(57) **ABSTRACT**

The present invention relates to an influenza antigen, comprising a fusion product of at least the extracellular part of a conserved influenza membrane protein or a functional fragment thereof and a presenting carrier, which may be a presenting (poly)peptide or a non-peptidic structure, such as glycans, peptide mimetics, synthetic polymers. The invention further relates to a vaccine against influenza, comprising at least an antigen of the invention, optionally in the presence of one or more excipients. The invention also relates to use of the antigen, a method for preparing the antigen and acceptor cells expressing the antigen.

14 Claims, 35 Drawing Sheets